Case closed! 96,032 patients, 671 hospitals, 6 continents. Patients who took #hydroxychroloquine 33-45% more likely to die; 2.4-5 X more likely to get heart arrhythmia. should withdraw emergency authorization today!
Hydroxychloroquine & chloroquine in hospitalized patients with #COVID19 This observational study of 96,000 people did not show benefit. Drugs were "...associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias"
Both and mentioned this Lancet paper as one main reason for concern
Belangrijke studie in The Lancet. Analyse van gegevens van >96.000 COVID19 patiënten laat geen gunstig effect zien van hydroxychloroquine of chloroquine alleen of met azithromycine. In tegendeel... Important study published in The Lancet!
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis . A large study again showing ZERO benefit of HCQ or CQ in the treatment of COVID19 with significant RISK of CV events including death
Real-life observational study using patient registries and dominated by US hospitals, but it's an international and massive data set so well worth a read. RCTs need to complete, to provide definitive answers, as long as robust safety monitoring is in place
“We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for #COVIDー19. They were associated with decreased in-hospital survival and an increased freq of ventricular arrhythm.”
Estudo publicado hoje na revista científica evidencia mais uma vez a ineficiência da (Hidroxi-)Cloroquina em tratamentos de #COVID19. O estudo acompanhou *96.032 pacientes*, em *671 hospitais* em *6 continentes*. 💊 Fonte:
Beaucoup vont éplucher la grosse étude observationnelle qui vient de sortir dans le sur 96.032 #COVID19 dont 14.888 traités avec l’#hydroxychroloquine ou la Chloroquine ± #azithromycine L’étude est ici et c’est terrible...
L'étude observationnelle du Lancet est une mine d'or. J'ai beaucoup de choses à dire dessus. Le thread va être un peu long. Mais tout d'abord : IL FAUT ARRETER TOUS LES ESSAIS AVEC L'HYDROXYCHLOROQUINE. Il devient clair que ce traitement tue + de gens !
Another poorly designed interpretation of a #HCQ data set for #COVID19. A larger poorly designed "trial" only leads to larger erroneous conclusions. For analysis, see the thread👇
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis * 96K patients * Each drug combination was associated with *lower* survival and more ventricular arrhythmias.
Lancet paper on hydrixychloroquine. Over 96K patients. Sadly no benefit and if anything damaging. We move on to other hopes. ‘We were unable to confirm a benefit of hydroxychloroquine or chloroquine’ ‘increased frequency of ventricular arrhythmias’.
Here's why I think this #hrdoxychloroquine "study" data is fake A thread.... @99freemind
Gut check. Would I, an ER doc, take: Remdesivir: Probably. Much yet to learn, but as of now, likely faster recovery +decent safety profile. Hydroxychloroquine: No. And given data so far, you couldn’t pay me to enroll in a trial.
New observational study in of >96,000 hospitalized patients across 671 hospitals and 6 continents finds that #hydroxychloriquine use for #COVID19 associated with ⬆ death AND ≈2.4-fold ⬆ ventricular arrhythmia.
In today, study of 96,032 patients with COVID - chloroquine +/- macrolide (like azithromycin) - hydroxychloroquine +/- - control (none of these) Each of these 4 treatments were independently associated with increased risk of in-hospital death
Yet another negative study on late HCQ treatment in sick hospitalized COVID-19 patients (13.2% in control group needed ventilation and/or died). To the authors' credit, they do say this data does NOT apply to treatment in an ambulatory/outpatient setting.
NEW study on #hydroxychloroquine & #chloroquine 👉🏾 671 hospitals in six continents 👉🏾 96 032 patients (mean age 53·8 years, 46·3% women) ‼️NO BENEFIT ‼️CARDIAC TOXICITY ‼️HIGHER MORTALITY IN HOSPITAL (even worse w/macrolide) 🧵
Taking HCQ is as strongly associated with increased coronavirus death risk as DIABETES.
I have been skeptical about this drug from the outset, but these sorts of studies are not what we need; we need an RCT; some are ongoing, and God help researchers try to recruit given the constantly shifting extreme headlines about this agent
Trying to digest the new lancet study of hydroxychloroquine that finds association between drug and increased in-hospital mortality among hospitalized patients with covid. Can't do full thread, but few thoughts.
In a wake of this large observational study on >90,000 #COVID19 patients on #hydroxychloroquine (HCQ), there are series of comment regarding the treatment efficacy, the overhype and potential harm to patients. So here is a thread
#Chloroquine ou Hydroxychloro seule ou avec Azythromycine. Près de 100 000 patients analysés dans 671 hôpitaux sur tous les continents. Aucun bénéfice dans le traitement du #COVID-19 mais que des dégâts irréversibles sur le cœur des patients. Quel gâchis!
I'm sorry, folks, but HCQ does not work against COVID-19.
In - study today compares outcomes for Covid patients who got usual care or chloroquine/hydroxychloroquine with or without a macrolide antibiotic (e.g. azithromycin). Main finding - these treatments appear to worsen mortality a lot, but ....1/n
Giving hydroxychloroquine to hospitalized COVID-19 patients is associated with an increased risk of death. At this point, doctors who are continue treating COVID-19 patients with hydroxychloroquine are just about committing malpractice.
1 in 6 #COVID19 hospitalised patients taking Trump's hydroxychloroquine die compared with 1 in 11 not, with zero evidence of any benefit
Always potential confounding with observational study. But, hard to imagine how a 30-40% increase in mortality from hydroxychloroquine will be turned into reduced mortality/improved clinical benefit in a RCT. The best is probably equivalence with placebo.
Any doctor continuing empiric novel treatments for covid outwith the context of a regulated clinical trial needs to take a long hard look at themselves.
Registerstudie på 90 tusen pat. Behandling med klorokin vid covid-19 "independently associated with an increased risk of in-hospital mortality...increased risk of de-novo ventricular arrhythmia during hospitalisation"
In : #Hydroxychloroquine shows no benefit for #COVID. Drug assoc w/ "decreased in-hospital survival & > freq of ventricular arrhythmias" Confirms warning on drug touts & is personally taking. Public mustn't model behavior.
While today's Lancet study was not designed to look at a potential benefit of statins and ACEI meds in COVID, unadjusted for other confounding factors, both meds were associated with an improved survival, along with being female which was previously known.
So...Hydroxychloroquine or chloroquine with or without a macrolide is associated with an INCREASED risk of mortality in COVID-19. If you know any presidents taking these drugs maybe suggest they stop...
"We were unable to confirm a benefit of #hydroxychloroquine or #chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19." cc
Great article in the ⁦ of >96K with #HCQ or #CQ +/- macrolide showing each drug regimen a/w decreased hospital survival and increased frequency of ventricular arrhythmias when used for treatment of #COVID-19 —>HCQ & CQ do NOT work for COVID19
👉 sets the debate on Hydroxychloroquine for #COVID19 with this multinational analysis of N=96032 patients: —> no confirmed benefit —> worse, association with decreased in-hospital survival & an increased frequency of ventricular arrhythmias
"In recent studies of hospitalised patients, 42% were shown to be hypomagnesaemic. However, physicians request magnesium testing in only 7% of these patients."
How is it possible that they would have this much data? . Not one of their sites is listed or acknowledged? They claim to have breathtaking data.
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of #Covid_19 a multinational registry analysis: no benefit & increased risk of death #covid19 - ⁦
Hydroxychloroquine or chloroquine +/- macrolide for #COVID19 Tx: a multinational registry analysis [May 22, 2020] et al. #CCC19 #COVID19ClinicalTrials Each drug regimen assoc w/ decreased in-hospital survival & ventricular arrhythmias
Hydroxychloroquine or chloroquine +/- a macrolide for treatment of COVID-19 :"unable to confirm a benefit .." It is a real world registry study. The lack of a benefit signal is very informative. A randomized control trial is the ultimate test
Just out on a large multinational registry of almost 100k #COVIDー19 pts 15k pts treated w/ CQ/#HCQ +\- macrolides compared w/ 80k untreated pts ‼️treatment w/ CQ/HCQ +/- macrolides associated w/ DECREASED in-hospital survival & ⬆️arrhytmias
I just finished reading this study, and it strikes me as very solidly done. (I'm not an epidemiologist or medical researcher, however, so take it for what it's worth.) Thread.
Hydroxychloroquine or chloroquine +/- macrolide for #COVID19 Tx: a multinational registry analysis [May 22, 2020] et al. #CCC19 #COVID19ClinicalTrials Each drug regimen assoc w/ decreased in-hospital survival & ventricular arrhythmias
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of #COVID-19: a multinational registry analysis
.......We were unable to confirm a benefit of hydroxychloroquine or chloroquine, when used alone or with a macrolide, on in-hospital outcomes for COVID-19
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
A few days ago, I was criticized for sharing an anecdote about this topic. Try this. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
#Hydroxychloroquine or #chloroquine +/- azithromyxin is linked to increased risk of death in analysis of 96,000 #coronavirus patients - those treated were also more likely to have cardiac arrhythmias. In